Bosiling Fluoxetine Hydrochloride Oral Solution

1. Indications and Usage
Major Depressive Disorder (MDD): Treatment of depressive episodes in adults and pediatric patients.
Obsessive-Compulsive Disorder (OCD): Treatment of OCD in adults and pediatric patients (typically ≥7 years).
Bulimia Nervosa: Treatment of binge-eating and purging behaviors in adult patients.
Panic Disorder: Treatment of panic disorder with or without agoraphobia in adults.
2. Dosage and Administration
Route of Administration: Oral administration ONLY. Use the provided calibrated dosing device for accurate measurement.
Adults (MDD/OCD): Recommended starting dose is 20 mg/day, usually in the morning. May increase to 80 mg/day if needed.
Pediatric Patients: Dosing varies by age and condition (e.g., MDD ≥8 years: start 10 mg/day, increase to 20 mg/day).
Bulimia Nervosa: Recommended dose is 60 mg/day.
Critical Administration Instructions:
Washout Period: Must discontinue at least 5 weeks before initiating a Monoamine Oxidase Inhibitor (MAOI).
Missed Dose: Take as soon as remembered, but do not double the dose.
3. Mechanism of Action
5-HT Reuptake Inhibition: Fluoxetine selectively inhibits the reuptake of serotonin (5-HT) in the central nervous system.
Synaptic Concentration: This increases the concentration of 5-HT in the synaptic cleft, enhancing serotonergic neurotransmission.
Active Metabolite: It is metabolized into norfluoxetine, which has a longer half-life and contributes to the therapeutic effect.
4. Safety and Warnings
Suicidal Thoughts: Antidepressants increase the risk of suicidal thinking and behavior in children, adolescents, and young adults; close monitoring is required.
Serotonin Syndrome: A potentially fatal condition may occur when co-administered with other serotonergic drugs or triptans. Signs include mental status changes, autonomic instability, and neuromuscular abnormalities.
Mania/Hypomania: May precipitate a mixed or manic episode in patients with Bipolar Disorder.
Bleeding Risk: May increase the risk of bleeding events when used with NSAIDs, aspirin, warfarin, etc.
QT Prolongation: Can cause QT interval prolongation; caution in patients with cardiovascular risk factors.
5. Adverse Reactions and Clinical Research
Most Common Adverse Reactions: Nausea, insomnia, somnolence, fatigue, anxiety, dry mouth, diarrhea, and decreased appetite.
Pediatric Considerations: Behavioral activation (e.g., agitation, aggression, irritability) is a concern in pediatric populations.
Clinical Research Highlights: Multiple randomized controlled trials have demonstrated efficacy in reducing depression ratings and OCD symptoms compared to placebo.
6. Drug Interactions
MAOIs: Contraindicated due to the risk of serotonin syndrome.
CYP2D6 Substrates: Fluoxetine is a strong CYP2D6 inhibitor; it may increase plasma concentrations of drugs metabolized by 2D6 (e.g., thioridazine, pimozide, tricyclic antidepressants).
Serotonergic Drugs: Concomitant use with other SSRIs, SNRIs, triptans, or tramadol increases the risk of serotonin syndrome.
Warfarin: May potentiate the anticoagulant effect, leading to increased INR and bleeding risk.
7. Pharmaceutical Information
Chemical Composition: Active Ingredient: Fluoxetine Hydrochloride.
Appearance: Clear, colorless to pale yellow liquid with a characteristic odor.
Packaging: Amber glass bottles or plastic bottles (e.g., 30 mL, 50 mL), typically 20 mg/5 mL concentration.
Storage: Store at controlled room temperature (20°C to 25°C); protect from light. Discard unused solution 90 days after opening.